Leadership changes at Oncopeptides

The board of directors of Oncopeptides AB has appointed Marty J. Duvall as CEO. Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Lindberg assumes the role of chief scientific officer, replacing MD Christian Jacques, who has held the position as CSO since 2018. Jacques will continue as a senior advisor.

Managers say Duvall brings extensive global commercialization skills from executive leadership roles in pharma and biotech including unique experience from the oncology and hematology space. Most recently he was the CEO of Tocagen Inc.

“The submission of the New Drug Application to the FDA, which was announced earlier today, marks an important inflection point for Oncopeptides,” says Per Wold-Olsen, chairman of Oncopeptides. “As we embark on the next phase of our journey, I am very happy to announce that Jakob will continue his dedicated scientific engagement in Oncopeptides as CSO and that we have been able to attract an industry leader like Marty as CEO in Oncopeptides. Marty will lead the transformation of Oncopeptides into a fully-fledged integrated global biotech company, headquartered in Stockholm, Sweden.”

“I am excited to join Oncopeptides to lead the company through its next phase and engage in the commercialization of melflufen,” Duvall says. “I am impressed by Oncopeptides’ strong scientific platform and our compelling Phase II data. With melflufen, I strongly believe that we have the potential to add significant value to patients with multiple myeloma who in many cases lack treatment options.”

“I am thrilled to get the opportunity to dedicate my time to exploit the potential of our unique PDC-platform and drive the scientific agenda beyond melflufen”, Lindberg says. “Our technology platform is truly exciting; it enables us to broaden the indications and provide new drug candidates that will be instrumental for the long-term growth of Oncopeptides.”